Élisabeth Martin
Université de Montréal
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Élisabeth Martin.
Milbank Quarterly | 2007
Marie-Pascale Pomey; Pierre-Gerlier Forest; Howard A. Palley; Élisabeth Martin
In January 1997, the government of Quebec, Canada, implemented a public/private prescription drug program that covered the entire population of the province. Under this program, the public sector collaborates with private insurers to protect all Quebecers from the high cost of drugs. This article outlines the principal features and history of the Quebec plan and draws parallels between the factors that led to its emergence and those that led to the passage of the Medicare Prescription Drug, Improvement and Modernization Act (MMA) in the United States. It also discusses the challenges and similarities of both programs and analyzes Quebecs ten years of experience to identify adjustments that may help U.S. policymakers optimize the MMA.
Journal of Pain Research | 2014
Lyne Lalonde; Manon Choinière; Élisabeth Martin; Djamal Berbiche; Sylvie Perreault; David Lussier
Background The economic burden of chronic noncancer pain (CNCP) remains insufficiently documented in primary care. Purpose To evaluate the annual direct health care costs and productivity costs associated with moderate to severe CNCP in primary care patients taking into account their pain disability. Materials and methods Patients reporting noncancer pain for at least 6 months, at a pain intensity of 4 or more on a 0 (no pain) to 10 (worst possible pain) intensity scale, and at a frequency of at least 2 days a week, were recruited from community pharmacies. Patients’ characteristics, health care utilization, and productivity losses (absenteeism and presenteeism) were documented using administrative databases, pharmacies’ renewal charts, telephone, and self-administered questionnaires. Patients were stratified by tertile of pain disability measured by the Brief Pain Inventory questionnaire. Results Patients (number =483) were, on average, 59 years old, mainly women (67.5%), and suffered from CNCP for a mean of 12 years at an average pain intensity of 6.5±1.9. The annual direct health care costs and productivity costs averaged CAD
Canadian Pharmacists Journal | 2013
Joanie Hébert; Marie-Claude Laliberté; Djamal Berbiche; Élisabeth Martin; Lyne Lalonde
9,565 (±
Pain Research & Management | 2014
Lyne Lalonde; Vincent Leroux-Lapointe; Manon Choinière; Élisabeth Martin; David Lussier; Djamal Berbiche; Diane Lamarre; Robert Thiffault; Ghaya Jouini; Sylvie Perreault
13,993) and CAD
Journal of Pain Research | 2014
Ghaya Jouini; Manon Choinière; Élisabeth Martin; Sylvie Perreault; Djamal Berbiche; David Lussier; Eveline Hudon; Lyne Lalonde
7,072 (±
Family Practice | 2012
Lyne Lalonde; Johanne Goudreau; Eveline Hudon; Marie-Thérèse Lussier; Fabie Duhamel; Danielle Bélanger; Lise Lévesque; Élisabeth Martin
11,716), respectively. The use of complementary health care services accounted for almost 50% of the direct health care costs. The mean adjusted total direct health care costs (considering pain-related hospitalizations only) and productivity costs increased with more pain disability: low disability, CAD
Journal of Pain Research | 2015
Lyne Lalonde; Manon Choinière; Élisabeth Martin; Lise Lévesque; Eveline Hudon; Danielle Bélanger; Sylvie Perreault; Anaïs Lacasse; Marie-Claude Laliberté
12,118; moderate, CAD
Canadian Journal of Pain | 2017
Elie Antaky; Lyne Lalonde; Mireille E. Schnitzer; Élisabeth Martin; Djamal Berbiche; Sylvie Perreault; David Lussier; Manon Choinière
18,278; and severe, CAD
Journal of Clinical Pharmacy and Therapeutics | 2018
Mylène Chartrand; Lyne Lalonde; Ariane Cantin; Alexandre Lahaie; Bojan Odobasic; Marie-Philip Tremblay; Dana Wazzan; Marie-Mireille Gagnon; Élisabeth Martin; Marc Dorais; Djamal Berbiche; Line Guénette
19,216; P=0.001. Conclusion The economic burden of CNCP is substantial and increases with the level of pain disability, which suggests the need for and potential benefits of improving CNCP management through specific and adapted treatment plans targeting the impact of pain on daily functioning.
American Journal of Kidney Diseases | 2017
Lyne Lalonde; Patricia Quintana-Bárcena; Anne Lord; Robert Bell; Valérie Clément; Anne-Marie Daigneault; Marie-Ève Legris; Sara Letendre; Marie Mouchbahani; Ghaya Jouini; Joelle Azar; Élisabeth Martin; Djamal Berbiche; Stephanie Beaulieu; Sébastien Beaunoyer; Émilie Bertin; Marianne Bouvrette; Noémie Charbonneau-Séguin; Jean-François Desrochers; Katherine Desforges; Ariane Dumoulin-Charette; Sébastien Dupuis; Maryame El Bouchikhi; Roxanne Forget; Marianne Guay; Jean-Phillippe Lemieux; Claudia Morin-Bélanger; Isabelle Noël; Stéphanie Ricard; Patricia Sauvé
Background: Practice-based research networks (PBRNs) are groups of practitioners and researchers with an interest in designing, evaluating and disseminating solutions to the real-world problems of clinical practices. Objective: To evaluate the level of interest of community pharmacists in participating in a PBRN and to document the services such a network should offer. Method: In a survey of community pharmacists in Montreal, Quebec, and surrounding areas, a questionnaire was mailed to a random sample of 1250 pharmacists. Two of the 28 questions were related to PBRNs: one assessed the pharmacists’ interest in participating in a PBRN; the other sought their views on which services and activities this network should offer. Results: In total, 571 (45.7%) pharmacists completed the questionnaire, but 6 did not answer the questions about the PBRN. Of the respondents, 58.9% indicated they were “very interested” or “interested” in joining a PBRN, while 41.1% reported little or no interest. The most popular potential services identified were access to clinical tools developed in research projects (77.0%), access to continuing education training programs developed in research projects (75.9%), information about conferences on pharmacy practice research (64.1%) and participation in the development of new pharmaceutical practices (56.1%). Conclusion: This study suggests that the level of interest that community pharmacists have in PBRNs is sufficient to further evaluate how such networks may optimize and facilitate pharmacy practice research. Can Pharm J 2013;146:47-54.